DOI QR코드

DOI QR Code

Application of Laboratory Medicine in the Field of Oral Medicine

  • Moon-Jong, Kim (Department of Oral Medicine, Gwanak Seoul National University Dental Hospital)
  • Received : 2022.09.06
  • Accepted : 2022.11.04
  • Published : 2022.12.30

Abstract

Various diseases of the orofacial region that are treated in the field of oral medicine not only are associated with local factors but may also be affected by systemic factors. Knowledge about laboratory medicine is needed to identify the systemic factors that can influence these diseases. Therefore, oral medicine specialists should be able to use diagnostic tests of laboratory medicine and interpret the results in diagnosing and treating diseases in the field of oral medicine. The aim of this article is to examine the diagnostic tests used in laboratory medicine that might be applied to assess the systemic aspect of diseases in the field of oral medicine and to interpret the significance of the findings.

Keywords

References

  1. Lippi G, Plebani M. A modern and pragmatic definition of Laboratory Medicine. Clin Chem Lab Med 2020;58:1171.
  2. Glick M, Greenberg MS, Lockhart PB, Challacombe SJ. Burket's oral medicine. 13th ed. Hoboken: Wiley-Blackwell; 2021.
  3. Olson JA, Feinberg I, Silverman S Jr, Abrams D, Greenspan JS. Serum vitamin B12, folate, and iron levels in recurrent aphthous ulceration. Oral Surg Oral Med Oral Pathol 1982;54:517-520. https://doi.org/10.1016/0030-4220(82)90189-X
  4. Jurge S, Kuffer R, Scully C, Porter SR. Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis 2006;12:1-21.
  5. Lu SY. Perception of iron deficiency from oral mucosa alterations that show a high prevalence of Candida infection. J Formos Med Assoc 2016;115:619-627. https://doi.org/10.1016/j.jfma.2016.03.011
  6. McCord C, Johnson L. Oral manifestations of hematologic disease. Atlas Oral Maxillofac Surg Clin North Am 2017;25:149-162. https://doi.org/10.1016/j.cxom.2017.04.007
  7. Askmark H, Wiholm BE. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990;81:131-140.
  8. Blackburn SC, Oliart AD, Garcia Rodriguez LA, Perez Gutthann S. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998;18:1277-1283.
  9. Chifman J, Laubenbacher R, Torti SV. A systems biology approach to iron metabolism. Adv Exp Med Biol 2014;844:201-225. https://doi.org/10.1007/978-1-4939-2095-2_10
  10. Reznik DA. Oral manifestations of HIV disease. Top HIV Med 2005;13:143-148.
  11. Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. infections in patients with diabetes mellitus. J Clin Med 2019;8:76.
  12. Dallman PR. Iron deficiency and the immune response. Am J Clin Nutr 1987;46:329-334.
  13. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13:350-365. https://doi.org/10.1177/154411130201300405
  14. Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004;151:1172-1181. https://doi.org/10.1111/j.1365-2133.2004.06257.x
  15. Garcia-Pola MJ, Llorente-Pendas S, Seoane-Romero JM, Berasaluce MJ, Garcia-Martin JM. Thyroid disease and oral lichen planus as comorbidity: a prospective case-control study. Dermatology 2016;232:214-219. https://doi.org/10.1159/000442438
  16. De Porras-Carrique T, Ramos-Garcia P, Aguilar-Diosdado M, Warnakulasuriya S, Gonzalez-Moles MA. Autoimmune disorders in oral lichen planus: a systematic review and meta-analysis. Oral Dis 2022. doi: 10.1111/odi.14127. [Epub ahead of print]
  17. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003;14:275-291. https://doi.org/10.1177/154411130301400405
  18. Kim MJ, Kim J, Kho HS. Comparison between burning mouth syndrome patients with and without psychological problems. Int J Oral Maxillofac Surg 2018;47:879-887. https://doi.org/10.1016/j.ijom.2018.02.001
  19. Boyce HW, Bakheet MR. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol 2005;39:89-97.
  20. Freudenreich O. Drug-induced sialorrhea. Drugs Today (Barc) 2005;41:411-418. https://doi.org/10.1358/dot.2005.41.6.893628
  21. Shiboski CH, Shiboski SC, Seror R, et al. 2016 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017;76:9-16. https://doi.org/10.1136/annrheumdis-2016-210571
  22. Baer AN, McAdams DeMarco M, Shiboski SC, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjogren's syndrome. Ann Rheum Dis 2015;74:1557-1561. https://doi.org/10.1136/annrheumdis-2014-206683
  23. Guo YP, Wang CG, Liu X, et al. The prevalence of antinuclear antibodies in the general population of china: a cross-sectional study. Curr Ther Res Clin Exp 2014;76:116-119. https://doi.org/10.1016/j.curtheres.2014.06.004
  24. Olson L, Eckerdal O, Hallonsten AL, Helkimo M, Koch G, Gare BA. Craniomandibular function in juvenile chronic arthritis. A clinical and radiographic study. Swed Dent J 1991;15:71-83.
  25. Akerman S, Kopp S, Nilner M, Petersson A, Rohlin M. Relationship between clinical and radiologic findings of the temporomandibular joint in rheumatoid arthritis. Oral Surg Oral Med Oral Pathol 1988;66:639-643. https://doi.org/10.1016/0030-4220(88)90308-8
  26. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581. https://doi.org/10.1002/art.27584
  27. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324. https://doi.org/10.1002/art.1780310302
  28. Wu CY, Yang HY, Luo SF, Lai JH. From rheumatoid factor to anticitrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci 2021;22:686.
  29. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870-874. https://doi.org/10.1136/ard.62.9.870
  30. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48. https://doi.org/10.1111/j.1749-6632.1982.tb22124.x
  31. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-1485.
  32. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-586. https://doi.org/10.1002/art.30129